Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°£¾ÏÀÇ Á¤»óÁ¶Á÷¼Õ»óÈ®·üÀ» ÀÌ¿ëÇÑ ¹æ»ç¼±°£¿°ÀÇ ¹ß»ý¿©ºÎ ¿¹Ãø°¡´É¼º¿¡ °üÇÑ ¿¬±¸ The Use of Normal Tissue Complication Probability to Predict Radiation Hepatitis

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2000³â 18±Ç 4È£ p.277 ~ 282
¼Ò¼Ó »ó¼¼Á¤º¸
±Ý±ââ/Ki Chang Keum ¼ºÁø½Ç/¼­Ã¢¿Á/ÀÌ»ó¿í/Á¤ÀºÁö/½ÅÇö¼ö/±è±Í¾ð/Jinsil Seong/Chang Ok Suh/Sang-wook Lee/Eun Ji Chung/Hyun Soo Shin/Gwi Eon Kim

Abstract

¸ñ Àû : ¹æ»ç¼±°£¿°(radiation hepatitis)ÀÇ ¹ß»ý¿¡´Â ¹æ»ç¼± Á¶»ç·®, Á¶»çüÀû µîÀÇ ¿äÀÎÀÌ ÀÛ¿ëÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ¿ÔÀ¸³ª ÀÌ·¯ÇÑ ¿äÀεéÀÇ °ü°è¸¦ ¾çÀûÀ¸·Î ³ªÅ¸³»Áö´Â ¸øÇÏ¿´´Ù. ±×·¯³ª ÃÖ±Ù 3Â÷¿ø ÀÔüÁ¶ÇüÄ¡·á°èȹü°èÀÇ ¹ßÀüÀ¸·Î °£¾ÏÀÇ ¹æ»ç¼±Á¶»ç½Ã °£ÀÇ
¼±·®-üÀû¿¡ ´ëÇÑ ºÐ¼®ÀÌ °¡´ÉÇÏ°Ô µÇ¾ú°í ³ª¾Æ°¡ À̸¦ ÀÌ¿ëÇÑ ¼öÇÐÀû º¯¼öÀÎ Á¤»óÁ¶Á÷¼Õ»óÈ®·üÀ» °è»êÇÒ ¼ö ÀÖ°Ô µÇ¾ú´Ù. ÀÌ¿¡ ÀúÀÚµéÀº Á¤»óÁ¶Á÷¼Õ»óÈ®·ü°ªÀ» ¿¬°è½ÃÄѼ­ ¹æ»ç¼±°£¿°ÀÇ ¿¹Ãø °¡´É¼ºÀ» Æò°¡ÇÏ°íÀÚ º» ¿¬±¸¸¦ ÁøÇàÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : 1992³â 3¿ùºÎÅÍ 1994³â 12¿ù »çÀÌ¿¡ ¹æ»ç¼± Ä¡·á¸¦ ¹ÞÀº ȯÀÚÁß¿¡¼­ °£¾Ï ȯÀÚ 10¸í, ´ãµµ¾Ï ȯÀÚ 10¸íÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. Ä¡·á Àü Ç÷ûÇÐÀû °Ë»ç¿¡¼­ °£¾Ï ȯÀÚ 2¸í¿¡¼­ °£°æÈ­°¡ ÀÖ¾ú°í (°¢°¢ÀÇ prothrombin time 73%, 68%) ´Ù¸¥ 18¸íÀÇ °£±â´ÉÀº
Á¤»óÀ̾ú´Ù. Á¶»çµÈ ¹æ»ç¼±·®Àº 1ÀÏ 1.8¡­2.0 Gy¾¿ 22ȸ¿¡¼­ 30ȸ¸¦ ½ÃÇàÇÏ¿© 39.6¡­60.0 Gy (Áß¾Ó°ªÀº 50.4 Gy)¿´À¸¸ç, Á¶»ç¸é¼ö´Â 2¡­6 ports (Áß¾Ó°ªÀº 4 ports)¿´´Ù. ÀÌ È¯ÀÚµéÀÇ Ä¡·á Àü Àü»êÈ­´ÜÃþÃÔ¿µÀ» ÀÌ¿ëÇÏ¿© °£ÀÇ ¼±·®Ã¼ÀûºÐ¼® ¹× LymanÀÇ °ø½ÄÀ»
Àû¿ëÇÏ¿©
Á¤»óÁ¶Á÷¼Õ»óÈ®·ü°ªÀ» ±¸ÇÏ¿´´Ù. ¹æ»ç¼±°£¿°Àº alkaline phosphataseÀÇ °ªÀÌ 2¹èÀÌ»ó Áõ°¡ µÇ°í ºñ¾Ï¼º º¹¼ö°¡ µ¿¹ÝµÈ °æ¿ì·Î Á¤ÀÇÇÏ¿´À¸¸ç ȯÀÚÀÇ º´·Â ±â·ÏÀ» ÀÌ¿ëÇÏ¿© ¹æ»ç¼±°£¿° ¹ß»ý¿©ºÎ¸¦ ÆľÇÇÏ¿© Á¤»óÁ¶Á÷¼Õ»óÈ®·ü°ª°ú »ó°ü °ü°è¸¦ ºÐ¼®ÇÏ¿´´Ù.
°á °ú : Á¤»óÁ¶Á÷¼Õ»óÈ®·ü°ªÀº 0.001¡­0.840±îÁö ºÐÆ÷ÇÏ¿´°í Áß¾Ó°ªÀº 0.05¿´´Ù. ¹æ»ç¼±°£¿°Àº ¹æ»ç¼± Ä¡·áÈÄ ¾à1ÁÖ¿¡¼­ 5ÁÖ»çÀÌ¿¡ 20¸íÁß 3¸í¿¡¼­ ¹ß»ýÇÏ¿´À¸¸ç, À̵éÀÇ Á¤»óÁ¶Á÷¼Õ»óÈ®·ü°ªÀº °¢°¢ 0.390, 0.528, 0.844 (Æò±Õ°ª 0.58¡¾0.23)À̾ú°í, ¹æ»ç¼±°£¿°ÀÌ
»ý±âÁö
¾ÊÀº ȯÀÚÀÇ Á¤»óÁ¶Á÷¼Õ»óÈ®·ü°ªÀº 0.001¡­0.308 (Æò±Õ°ª 0.09¡¾0.09) »çÀÌ¿¡ ºÐÆ÷ÇÏ¿´´Ù. Á¤»óÁ¶Á÷¼Õ»óÈ®·üÀ» üÀûÀÎÀÚ°¡ 0.32·Î °è»êÇÑ °æ¿ì¿¡´Â ºñ±³Àû ³ôÀº °ªÀÎ 0.39À̻󿡼­ ¹æ»ç¼± °£¿°ÀÌ ¹ß»ýÇÑ °ÍÀ» ¾Ë ¼ö ÀÖÀ¸³ª, n À» 0.69·Î ÇÏ¿© °è»êÇÑ °æ¿ì¿¡´Â
ºñ±³Àû
³·Àº
Á¤»óÁ¶Á÷¼Õ»óÈ®·ü(0.03, 0.18)¿¡¼­µµ ¹æ»ç¼± °£¿°ÀÌ ¹ß»ýÇÏ´Â °ÍÀ» º¸¿© üÀûÀÎÀÚ 0.32°¡ ºñ±³Àû ÀÓ»óÀû °á°ú¿Í ÀÏÄ¡ÇÏ´Â °ªÀ̾ú´Ù.
°á ·Ð : Á¤»óÁ¶Á÷¼Õ»óÈ®·ü°ªÀÌ ÀÏÁ¤°ª ÀÌ»óÀÇ È¯ÀÚ¿¡¼­ ¹æ»ç¼±°£¿°ÀÌ ¹ß»ýÇÏ´Â °ÍÀ¸·Î º¸¾Æ Á¤»óÁ¶Á÷¼Õ»óÈ®·ü°ªÀ¸·Î ¹æ»ç¼±°£¿°ÀÇ ¹ß»ýÀ» ¿¹ÃøÇÒ ¼ö ÀÖÀ» °ÍÀÌ´Ù.

Purpose : Although It has been known that the tolerance of the liver to external beam irradiation depends on the irradiated volume and dose, few data exist which quantify this dependence. However, recently, with the development of three
dimensional
(3-D) treatment planning, have the tools to quantify the relationships between dose, volume, and normal tissue complications become available. The objective of this study is to investigate the relationships between normal tissue complication
probability
(NTCP) and the risk of radiation hepatitis for patients who received variant dose partial liver irradiation.
Materials and Method : From March 1992 to December 1994, 10 patients with hepatoma and 10 patients with bile duct cancer were included in this study. Eighteen patients had normal hepatic function, but 2 patients (prothrombin time 73%, 68%) had
mild
liver cirrhosis before irradiation. Radiation therapy was delivered with 10MV linear accelerator, 180¡­200 cGy fraction per day. The total dose ranged from 3,960 cGy to 6,000 cGy (median dose 5,040 cGy). The normal tissue complication probability
was
calculated by using Lyman's model. Radiation hepatitis was defined as the development of anicteric elevation of alkaline phosphatase of at least two fold and non-malignant ascites in the absence of documented progressive.
Results : The calculated NTCP ranged from 0.001 to 0.840 (median 0.05). Three of the 20 patients developed radiation hepatitis. The NTCP of the patients with radiation hepatitis were 0.390, 0.528, 0.844 (median : 0.58¡¾0.23), but that of the
patients
without radiation hepatitis ranged from 0.001 to 0.308 (median : 0.09¡¾0.09). When the NTCP was calculated by using the volume factor of 0.32, a radiation hepatitis was observed only in patients with the NTCP value more than 0.39. By contrast,
clinical
results of evolving radiation hepatitis were not well correlated with NTCP value calculated when the volume factor of 0.69 was applied. On the basis of these observations, the volume factor of 0.32 was more correlated to predict a radiation
hepatitis.
Conclusion : The risk of radiation hepatitis was increased above the cut-off value. Therefore the NTCP seems to be used for predicting the radiation hepatitis.

Å°¿öµå

°£¾Ï; ¹æ»ç¼±°£¿°; Á¤»óÁ¶Á÷¼Õ»óÈ®·ü; Hepatocellular carcinoma; Radiation Hepatitis; Normal Tissue Complication Probability;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS